Testing Drugs For Resistant TB Seen As Prelude To Trials In Wider Population

A Phase II trial of Johnson & Johnson's investigational tuberculosis drug TMC207 is highlighted in a June 4 New England Journal of Medicine editorial by NIAID's Cliffton Barry, not only for its positive results, but for its contribution to encouraging trial designs that could facilitate TB drug development